Pietro Andreone

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant
    Maurizio Biselli
    Semeiotica Medica, Dipartimento di Medicina Clinica, Universitàdi Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    Clin Transplant 23:191-8. 2009
  2. ncbi Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection
    P Andreone
    Università di Bologna and Policlinico S Orsola, Italy
    Ann Intern Med 129:294-8. 1998
  3. ncbi Posttransplantation lymphoproliferative disorders
    Pietro Andreone
    Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Policlinico S Orsola Malpighi, Bologna, Italy
    Arch Intern Med 163:1997-2004. 2003
  4. ncbi Prophylaxis and treatment of hepatis B virus infection after liver transplantation
    P Andreone
    Policlinico S. Orsola-Malpighi, Via Massarenti, 9-40138 Bologna, Italy
    Transplant Proc 35:1022-4. 2003
  5. ncbi Interferon-alpha combined with ketoprofen as treatment of naïve patients with chronic hepatitis C: a randomized controlled trial
    P Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Italy
    J Viral Hepat 10:306-9. 2003
  6. ncbi In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C
    Pietro Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Cytokine 26:95-101. 2004
  7. ncbi Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study
    P Andreone
    Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Italy
    Dig Liver Dis 33:693-7. 2001
  8. ncbi In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C
    P Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Policlinico S Orsola, Via Massarenti, 9 40138 Bologna, Italy
    J Viral Hepat 8:194-201. 2001
  9. ncbi High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance
    P Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, 40138 Bologna, Italy
    J Viral Hepat 11:439-42. 2004
  10. ncbi Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial
    P Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Policlinico Sant Orsola, Via Massarenti, 9, 40138, Bologna, Italy
    Antiviral Res 49:75-81. 2001

Detail Information

Publications68

  1. ncbi Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant
    Maurizio Biselli
    Semeiotica Medica, Dipartimento di Medicina Clinica, Universitàdi Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    Clin Transplant 23:191-8. 2009
    ..002 and p < 0.001, respectively). No rejection episode was observed (three in controls). This study demonstrates the medium-term efficacy and safety of MMF plus low dose CNI in reducing nephrotoxicity in LT recipients...
  2. ncbi Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection
    P Andreone
    Università di Bologna and Policlinico S Orsola, Italy
    Ann Intern Med 129:294-8. 1998
    ..An association between monoclonal gammopathies and chronic liver diseases has been reported...
  3. ncbi Posttransplantation lymphoproliferative disorders
    Pietro Andreone
    Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Policlinico S Orsola Malpighi, Bologna, Italy
    Arch Intern Med 163:1997-2004. 2003
    ....
  4. ncbi Prophylaxis and treatment of hepatis B virus infection after liver transplantation
    P Andreone
    Policlinico S. Orsola-Malpighi, Via Massarenti, 9-40138 Bologna, Italy
    Transplant Proc 35:1022-4. 2003
  5. ncbi Interferon-alpha combined with ketoprofen as treatment of naïve patients with chronic hepatitis C: a randomized controlled trial
    P Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Italy
    J Viral Hepat 10:306-9. 2003
    ..Thus, the role of ketoprofen in the treatment of chronic hepatitis C needs to be further evaluated against such a treatment...
  6. ncbi In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C
    Pietro Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Cytokine 26:95-101. 2004
    ....
  7. ncbi Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study
    P Andreone
    Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Italy
    Dig Liver Dis 33:693-7. 2001
    ..Recurrence of hepatitis C after liver transplantation is almost constant and may lead to graft loss. The results of treatment with interferon and/or other agents have been controversial...
  8. ncbi In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C
    P Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Policlinico S Orsola, Via Massarenti, 9 40138 Bologna, Italy
    J Viral Hepat 8:194-201. 2001
    ....
  9. ncbi High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance
    P Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, 40138 Bologna, Italy
    J Viral Hepat 11:439-42. 2004
    ..4; 95% CI: 1.3-84.9). Our study suggests that the occurrence of lamivudine resistance increases the risk of hepatocellular carcinoma in anti-HBe positive cirrhosis and warrants further research...
  10. ncbi Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial
    P Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Policlinico Sant Orsola, Via Massarenti, 9, 40138, Bologna, Italy
    Antiviral Res 49:75-81. 2001
    ..It has been shown that vitamin E can increase the host immune response, and this may provide protection against infectious diseases...
  11. ncbi Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study
    P Andreone
    Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Italy
    Ital J Gastroenterol Hepatol 31:688-94. 1999
    ..Recently, in vitro and in vivo studies demonstrated that non-steroidal anti-inflammatory drugs are able to enhance the activity of interferon alpha...
  12. ncbi Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial
    P Andreone
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Università di Bologna Istituto Oncologico, Italy
    J Viral Hepat 11:69-73. 2004
    ..Higher doses and/ore more prolonged courses as well as the association with new interferon formulation such as pegylated interferons could improve the sustained response rates to this treatment...
  13. ncbi Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study
    Maurizio Biselli
    Department of Clinical Medicine, University of Bologna, Azienda Ospedaliero Universitaria, Policlinico S Orsola Malpighi, Bologna, Italy
    J Clin Gastroenterol 44:52-7. 2010
    ..Alcoholic liver cirrhosis (ALC) is a leading indication for orthotopic liver transplantation (OLT)...
  14. ncbi Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study
    Annagiulia Gramenzi
    Department of Clinical Medicine, University of Bologna, 40138 Bologna, Italy
    World J Gastroenterol 15:5946-52. 2009
    ....
  15. ncbi Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool
    Elisabetta Loggi
    Department of Clinical Medicine, University of Bologna, Bologna, Italy
    J Hepatol 56:579-85. 2012
    ..We assessed the clinical, serovirological, and immunological outcomes of liver transplant from HBsAg positive donors in a single centre study...
  16. ncbi Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation
    Pietro Andreone
    Department of Internal Medicine, Cardioangiology, and Hepatology, University of Bologna, S. Orsola Hospital, Via Massarenti, 9-40138 Bologna, Italy
    Transplantation 74:1119-24. 2002
    ..Not only does HBV-DNA suppression allow patients to be eligible for OLT, but the improvement of the patients' clinical status may delay the need for OLT in an era of organ shortage...
  17. ncbi A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C
    Annagiulia Gramenzi
    Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Policlinico S Orsola, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    J Gastroenterol 42:362-7. 2007
    ..Efficacy and safety of interferon induction therapy alone or in combination with ribavirin or ribavirin plus amantadine were evaluated in chronic hepatitis C patients who were nonresponders to primary antiviral treatment...
  18. ncbi Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner?
    Maurizio Biselli
    Department of Clinical Medicine, Alma Mater Studiorum Universita di Bologna, Bologna, Italy
    Liver Transpl 16:964-73. 2010
    ..In conclusion, MELD-sodium and integrated MELD were the best prognostic models to predict drop-out rates among patients awaiting LT...
  19. ncbi Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation
    F Lodato
    Department of Digestive Diseases and Internal Medicine, Azienda Ospedaliero Universitaria Policlinico Sant Orsola Malpighi, Bologna, Italy
    Aliment Pharmacol Ther 28:450-7. 2008
    ..Treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) is difficult with low response rates...
  20. ncbi Liver transplantation for patients with alcoholic liver disease: an open question
    Annagiulia Gramenzi
    Department of Clinical Medicine, University of Bologna, Semeiotica Medica, S Orsola Malpighi Hospital, Bologna, Italy
    Dig Liver Dis 43:843-9. 2011
    ..The main future goals are to formulate a well-defined pre-transplant approach and a single definition of alcohol relapse and to improve prevention strategies...
  21. ncbi Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a Western dual-center experience
    Matteo Cescon
    Liver and Multiorgan Transplant Unit, Department of Surgery and Transplantation, University of Bologna, Bologna, Italy
    Arch Surg 144:906-13. 2009
    ..The role of hepatitis B virus (HBV) infection in determining the prognosis after hepatectomy for hepatocellular carcinoma (HCC) in patients with cirrhosis is controversial...
  22. ncbi Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma
    Maria Stella De Mitri
    Department of Internal Medicine, Cardioangiology, Hepatology, University of Bologna, Bologna, Italy
    Liver Int 27:1126-33. 2007
    ....
  23. ncbi Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin
    Ranka Vukotic
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Bologna, Italy
    Liver Int 28:407-11. 2008
    ....
  24. ncbi High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
    S Berardi
    Dipartimento di Medicina Interna et Gastroenterologia, Universita di Bologna, Italy
    Gut 56:237-42. 2007
    ..Interferon may trigger autoimmune disorders, including autoimmune hepatitis, in immunocompetent patients. To date, no such disorders have been described in liver transplanted patients...
  25. ncbi Acquired intestinal lymphangiectasia successfully treated with a low-fat and medium-chain triacylglycerol-enriched diet in a patient with liver transplantation
    Maurizio Biselli
    Semeiotica Medica, Dipartimento Medicina Interna, Cardioangiologia ed Epatologia, , Policlinico S. Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Eur J Gastroenterol Hepatol 18:561-4. 2006
    ..Intestinal lymphangiectasia should be suspected in liver-transplanted patients developing hypoproteinaemia and hypoalbuminaemia after the recurrence of cirrhosis...
  26. ncbi Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft
    Elisabetta Loggi
    Department of Clinical Medicine, University of Bologna, Bologna, Italy
    J Hepatol 50:625-30. 2009
    ..Experience using HBsAg positive grafts is, however, very limited...
  27. ncbi Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study
    Maurizio Biselli
    Semeiotica Medica, Dipartimento Medicina Interna, Cardioangiologia ed Epatologia, , Via Massarenti 9, 40138 Bologna, Italy
    Clin Gastroenterol Hepatol 3:918-25. 2005
    ..Only TACE and CLIP score proved to be independent predictors of survival at multivariate analysis. CONCLUSIONS: TACE is an effective therapeutic option for cirrhotic patients with unresectable HCC and a CLIP score of 3 or less...
  28. ncbi Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study
    A Gramenzi
    Dipartimento di Medicina Clinica, Alma Mater Studiorum Universita di Bologna, Semeiotica Medica, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    J Viral Hepat 17:360-6. 2010
    ..003). Our results further emphasize the notion that chronic hepatitis C is becoming a disease of the elderly and that elderly patients with chronic HCV infection often have severe and underestimated disease...
  29. ncbi In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B
    E Loggi
    Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy
    J Viral Hepat 15:442-8. 2008
    ..These results need further investigations, but reinforce the idea of an immunotherapeutic approach for chronic hepatitis B...
  30. ncbi Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen
    M Biselli
    Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Via Massarenti 9, Italy
    Dig Liver Dis 38:27-32. 2006
    ..These results need to be confirmed by large studies...
  31. ncbi Long-term antiviral treatment for recurrent hepatitis C after liver transplantation
    Valentina Rosa Bertuzzo
    Department of General Surgery and Organ Transplantation, University of Bologna, Bologna, Italy
    Dig Liver Dis 44:861-7. 2012
    ..The management of patients treated for hepatitis C recurrence after liver transplantation and not achieving virological response following treatment with interferon plus ribavirin is controversial...
  32. ncbi Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension
    Annalisa Berzigotti
    Department of Internal Medicine, Ageing and Nephrology, University of Bologna, Policlinico S Orsola Malpighi, Via Albertoni 15, 40138 Bologna, Italy
    J Gastroenterol 46:687-95. 2011
    ..This study assessed the prognostic value of a single HVPG measurement and Doppler-ultrasound (US) evaluation in patients with cirrhosis and CSPH...
  33. ncbi Stem cells for end stage liver disease: how far have we got?
    Stefania Lorenzini
    Dipartimento di Medicina Clinica, Via Massarenti 9, Bologna, Italy
    World J Gastroenterol 14:4593-9. 2008
    ..This update aims to give non-stem cell specialists an overview of the results obtained to date in this fascinating field of biomedical research...
  34. ncbi Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C
    Alberto Grassi
    Department of Internal Medicine, Cardioangiology, Hepatology, University of Bologna Sant Orsola Malpighi Hospital, Bologna, Italy
    Liver Transpl 12:1673-81. 2006
    ..A high number of infected cells, independently from the genotype, represents a negative predictive factor of response to antiviral treatment...
  35. ncbi Allocation priority in non-urgent liver transplantation: An overview of proposed scoring systems
    S Gitto
    Department of Clinical Medicine, University of Bologna, Semeiotica Medica, Sant Orsola Malpighi Hospital, Bologna, Italy
    Dig Liver Dis 41:700-6. 2009
    ..In conclusion, several scoring systems have been described for organ allocation, but today, none is definitely able to overcome the limitations of the Child-Turcotte-Pugh and model for end-stage liver disease systems...
  36. ncbi Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis
    A Gramenzi
    Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, , Bologna, Italy
    Gut 48:843-8. 2001
    ..Patients who achieved sustained aminotransferase normalisation survived and did not develop any complications during follow up...
  37. ncbi Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection
    Roberto M Lemoli
    Institute of Hematology and Medical Oncology L and A Seragnoli, Bologna, Italy
    Stem Cells 24:2817-25. 2006
    ....
  38. ncbi Low replication and variability of HBV pre-core in concomitant infection with hepatitis B and hepatitis C viruses
    M S De Mitri
    Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy
    Arch Virol 152:395-404. 2007
    ..005). In conclusion, in HBV/HCV infection, the virological pattern was characterised by the dominance of HCV associated with lower HBV replication capacity and decreased emergence of HBV pre-C variants...
  39. ncbi Alcohol and viral hepatitis: a mini-review
    S Gitto
    Department of Medicine, University of Bologna, Bologna, Italy
    Dig Liver Dis 41:67-70. 2009
    ..Abstinence could reverse some of these deleterious effects...
  40. ncbi Genetic variability of hepatitis C virus in HBV/HCV co-infection and HCV single-infection
    M S De Mitri
    Department of Internal Medicine, Cardioangiology and Hepatology, Policlinico S Orsola Malpighi, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Arch Virol 150:261-71. 2005
    ..Furthermore, in the cases of HCV dominance, circulating HBV genomes did not have a significant effect on the viral heterogeneity of HCV...
  41. ncbi Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation
    Fabio Piscaglia
    Division of Internal Medicine, Department of Digestive Disease and Internal Medicine, St Orsola Malpighi University Hospital, Bologna, Italy
    Liver Transpl 16:658-67. 2010
    ..In conclusion, for a patient with HCC and portal vein thrombosis, appropriate investigations can establish whether the thrombosis is benign; patients with HCC and benign portal vein thrombosis are candidates for liver transplantation...
  42. ncbi Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma
    M S De Mitri
    Department of Internal Medicine, Cardioangiology, Hepatology, University of Bologna, Bologna, Italy
    J Viral Hepat 13:574-81. 2006
    ..The mutational pattern of the pre-C/C region was closely related to HBV replication efficiency, and specific HBV mutations selectively associated with HCV co-infection could be linked with accelerated HBV/HCV-related disease progression...
  43. ncbi Immunological modifications during treatment with thymosin alpha1 plus antiviral therapy in chronic hepatitis C
    E Grandini
    Department of Clinical Medicine, University of Bologna, Bologna, Italy
    Ann N Y Acad Sci 1194:147-52. 2010
    ..An accurate selection of HCV patients who can benefit from immunomodulation is needed...
  44. ncbi Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases
    S Lorenzini
    Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, and Department of Gastroenterology and Internal Medicine, Orsola Malpighi Hospital, Bologna, Italy
    Transplant Proc 38:1477-80. 2006
    ..They are often the result of Epstein-Barr virus (EBV)-induced proliferation of B-lymphocytes in the setting of immunosuppression...
  45. ncbi Relationship between hepatic haemodynamics assessed by Doppler ultrasound and liver stiffness
    Veronica Salvatore
    Department of Digestive Disease and Internal Medicine, Azienda Ospedaliero Universitaria di Bologna Policlinico S Orsola Malpighi, Bologna, Italy
    Dig Liver Dis 44:154-9. 2012
    ..We tested the relationship between hepatic haemodynamics assessed by Doppler ultrasonography and liver stiffness assessed by Transient Elastography in hepatitis C related chronic liver disease...
  46. ncbi Hepatocellular carcinoma in patients with cryptogenic cirrhosis
    Edoardo Giovanni Giannini
    Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Universita di Genova, Genova, Italy
    Clin Gastroenterol Hepatol 7:580-5. 2009
    ..We aimed to characterize the clinical features of patients diagnosed with HCC after CC during a 15-year period (1992-2006)...
  47. ncbi Regenerative medicine and liver injury: what role for bone marrow derived stem cells?
    Stefania Lorenzini
    Dipartimento di Medicina Interna, Cardioangiologia, Epatologia, Universita di Bologna, Bologna, Italy
    Curr Stem Cell Res Ther 2:83-8. 2007
    ..Our aim is to give scientists and clinicians who are interested in regenerative medicine the rational basis for planning future studies on stem cell therapy for liver diseases...
  48. ncbi Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection
    A Gramenzi
    Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, , Italy
    J Viral Hepat 12:525-30. 2005
    ....
  49. ncbi Cryoglobulinemia in elderly patients with HCV-related chronic hepatitis
    Francesco Giuseppe Foschi
    Francesco Giuseppe Foschi, Anna Chiara Dall Aglio, Arianna Lanzi, Giorgio Marano, Sara Savini, Giuseppe Francesco Stefanini, Department of Internal Medicine, Faenza Hospital, viale Stradone 9, 48018 Faenza RA, Italy
    World J Gastrointest Pharmacol Ther 1:72-4. 2010
    ....
  50. ncbi Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study
    Fabio Caputo
    G Fontana Centre for the Study and Multidisciplinary Treatment of Alcohol Addiction, Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Eur Neuropsychopharmacol 17:781-9. 2007
    ..The GHB/NTX combination was more effective than either drug given alone; this suggests that the two drugs combine their different actions synergistically without suppressing the favourable effects of each other...
  51. ncbi Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders
    Annalisa Berzigotti
    Dipartimento di Medicina Interna, Cardioangiologia, Epatologia, Policlinico S. Orsola-Malpighi, Via Albertoni 15, 40138 Bologna, Italy
    J Hepatol 44:310-6. 2006
    ..This can be considered a non-invasive clue for the a priori identification of this subgroup of patients...
  52. ncbi Soluble CD30 serum level in HCV-positive chronic active hepatitis: A surrogate marker of disease activity?
    F G Foschi
    Semeiotica Medica, Dipartimento di Medicina Interna, Cardioangiologia, Epatologia, Universita di Bologna, Bologna, Italy
    Cytokine 12:815-8. 2000
    ..5; P=0.006). The raised CD30s level found in more severe HCV liver disease indirectly suggests activation and expansion of Th(2)cells. CD30s levels could represent a useful surrogate marker of activity in chronic HCV infections...
  53. ncbi Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver
    Annagiulia Gramenzi
    Department of Clinical Medicine, University of Bologna, Via Massarenti 9, Bologna, Italy
    Dig Liver Dis 44:674-80. 2012
    ..The prevalence of hepatitis C virus infection increases with advancing age, but elderly hepatitis C virus patients remain an understudied population...
  54. ncbi Stem cell mobilization and collection in patients with liver cirrhosis
    S Lorenzini
    Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy
    Aliment Pharmacol Ther 27:932-9. 2008
    ..Bone marrow-derived stem cells (BMSC) and granulocyte colony-stimulating factor (G-CSF) have been proved to contribute to tissue regeneration after liver injury...
  55. ncbi Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a
    Giulia Morsica
    AIDS 18:1080-2. 2004
  56. ncbi Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
    Savino Bruno
    Liver Unit, Department of Medicine, AO Fatebenefratelli e Oftalmico, Milan, Italy
    Hepatology 45:579-87. 2007
    ..Irrespective of SVR achievement, all patients should continue surveillance because the risk of occurrence of HCC was not entirely avoided...
  57. ncbi Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis
    Tommaso Stroffolini
    Department of Gastroenterology, Ospedale San Giacomo, Roma, Italy
    Am J Gastroenterol 103:1966-72. 2008
    ....
  58. ncbi Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir
    Munira Hussain
    Division of Gastroenterology, University of Michigan Medical Center, 1500 East Medical Center Drive, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109-0362, USA
    J Clin Microbiol 44:1094-7. 2006
    ..Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier...
  59. ncbi Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USA
    J Hepatol 43:937-43. 2005
    ..CONCLUSIONS: In conclusion, adefovir resistance can be associated with significant viral rebound and hepatic decompensation which may be fatal...
  60. ncbi Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity
    Helen Cooksley
    Institute of Hepatology, University College London, 69 75 Chenies Mews, London WC1E 6HX, United Kingdom
    Antimicrob Agents Chemother 52:312-20. 2008
    ..In conclusion, T-cell reactivity to HBV increases in a proportion of ADV-treated patients and is associated with greater suppression of HBV replication and HBeAg loss...
  61. ncbi Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine
    Vito Di Marco
    Cattedra e U O C di Gastroenterologia, Clinica Medica, Universita di Palermo, Palermo, Italy
    Hepatology 40:883-91. 2004
    ..After 4 years of therapy, 39% of patients maintain a virological and biochemical response. Loss of virological response may lead to clinical deterioration in patients with cirrhosis...
  62. ncbi Hepatic artery stenosis in liver transplanted patients treated with pegylated interferon alpha-2b and ribavirin
    Maurizio Biselli
    Transplantation 78:953. 2004
  63. ncbi Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection
    Florian Bihl
    Division of Gastroenterology and Hepatology, University Hospital of Geneva, Geneva, Switzerland
    Liver Transpl 14:478-85. 2008
    ..Thus, the profile of the cellular immunity against HBV was in immune suppressed patients similar to subjects with chronic HBV infection with suppressed HBV-DNA...
  64. ncbi Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals
    Paola Rizza
    Section of Experimental Immunotherapy, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Viale Regina Elena, 299, 00161Rome, Italy
    Vaccine 26:1038-49. 2008
    ..We conclude that, under the conditions used in this trial, natural IFN-alpha does not act as an adjuvant of the HBV vaccine in healthy unvaccinated individuals...
  65. ncbi Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials
    Calogero Cammà
    National Council of Research, Istituto Metodologie Diagnostiche Avanzate, Palermo, Italy
    Radiology 224:47-54. 2002
    ..To review the available evidence of chemoembolization for unresectable hepatocellular carcinoma (HCC)...
  66. ncbi Stem cell therapy for human liver cirrhosis: a cautious analysis of the results
    Stefania Lorenzini
    Stem Cells 25:2383-4. 2007
    ..Well designed, randomized, controlled studies are needed to confirm preliminary results and eventually clear doubts...
  67. ncbi Effect of liver transplantation on tuftsin activity and phagocytic activity of neutrophil granulocytes in patients with liver cirrhosis
    Francesco Giuseppe Foschi
    Dipartimento di Medicina Interna, Ospedale per gli Infermi, Faenza, Italia
    Int Arch Allergy Immunol 137:258-62. 2005
    ..This effect is associated with an improvement of both functional hyposplenism and haematological hypersplenism. The restoration of natural defences against infections may mitigate the adverse effect of immunosuppressive treatment...
  68. ncbi Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire
    Anthony Tanoto Tan
    Singapore Institute for Clinical Sciences, A STAR, Brenner Centre for Molecular Medicine, 30 Medical Drive, Singapore
    J Virol 82:10986-97. 2008
    ....